Search Results



Your search for Leonard Saltz, MD matches 14 pages

Showing 1 - 14


colorectal cancer

ASCP/CAP/AMP/ASCO Colorectal Cancer Biomarker Guideline: A Clinician's Perspective

The joint American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and ASCO guideline reported by Sepulveda et al, and reviewed in this issue of The ASCO Post, represents a collaboration of three pathology societies and ASCO ...

ASCO Value in Cancer Care Task Force

The Value in Cancer Care Task Force was established in 2007 to educate oncologists about the importance of discussing costs associated with recommended treatments, empower patients to ask questions about the anticipated costs of their treatment options, identify the drivers of the rising costs of...

2016 ASCO Annual Meeting Planning Committees

The ASCO Annual Meeting highlights the latest research and treatment advances in oncology, with nearly 30,000 oncology professionals attending each year. ASCO wishes to acknowledge the volunteers on this year’s Cancer Education and Scientific Program Committees and thank them for their time and...

Noted Gastrointestinal Oncologist Leonard Saltz, MD, Tempers Optimism With Reality and Factors Cost Into the Equation of Value in Cancer Care

Leonard Saltz, MD, was born in New York, New York, and reared in Westchester County, in the suburbs of the City. Terrance Archer, his high-school biology teacher, whom Dr. Saltz described as a “force of nature,” a wonderful human being, and a major role model, influenced his nascent curiosity in...

colorectal cancer

Next-Generation Sequencing Assay May Permit Accurate Detection of Mismatch Repair Deficiency in Colorectal Cancer

Use of a custom next-generation sequencing assay may accurately predict mismatch repair deficiency on the basis of mutational load in colorectal cancer, according to a report by Stadler et al in the Journal of Clinical Oncology. Study Details The study involved data from 224 patients with...

cost of care

Leonard Saltz, MD, on Issues of Value in Melanoma Treatment

Leonard Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses how the cost of care affects behavior and decision-making on the part of patients and oncologists.

colorectal cancer

Adding Cetuximab to Adjuvant Therapy with Modified FOLFOX6 Does Not Improve Survival

Adding cetuximab (Erbitux) to adjuvant treatment with mFOLFOX6, the modified sixth version of FOLFOX (leucovorin, fluorouracil, oxaliplatin) did not improve disease-free survival among patients with resected stage III colon cancer, even those with wild-type KRAS, according to a phase III study in...

cost of care

Oncologists Speak Out Against the High Cost of Cancer Drugs 

That the United States spends twice as much on health care than other industrialized countries—about $2.8 trillion in 2012—without reaping appreciably better outcomes1 is not news. The topic has been dissected on the front pages of leading newspapers for years and was the subject of the entire...

colorectal cancer

Neoadjuvant Chemotherapy Without Routine Radiotherapy Shows Promise in Patients With Locally Advanced Rectal Cancer

In a pilot study reported in the Journal of Clinical Oncology, Deborah Schrag, MD, MPH, and colleagues from Memorial Sloan Kettering Cancer Center, New York, assessed outcomes with neoadjuvant FOLFOX (fluorouracil, leucovorin, oxaliplatin)/bevacizumab (Avastin) with selective use of...

colorectal cancer

Observation Appropriate for Some Patients With Rectal Cancer Following Neoadjuvant Therapy

Some patients with rectal cancer who achieve a complete response to neoadjuvant chemoradiation therapy can be monitored for tumor recurrence and may never need surgery, according to a retrospective review from patients at Memorial Sloan Kettering Cancer Center, New York, presented at the 2015...

cost of care

Cost of Immunotherapy Projected to Top $1 Million per Patient per Year

If new immunotherapy combinations were administered to the half a million Americans dying of cancer each year, the nation’s price tag for treating them—for just 1 year—could top $174 billion, according to projections by Leonard Saltz, MD, Chief of Gastrointestinal Oncology and Chair of the Pharmacy ...

Expert Point of View: Peter B. Bach, MD, MAPP, and Leonard Saltz, MD

Peter B. Bach, MD, MAPP, Director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center (Memorial), New York, discussed Dr. Schrag’s study at the ASCO Health Services Research and Quality of Care session. “Dr. Schrag’s analysis could have been ‘back of the...

cost of care

Calculating the Value of Cancer Drugs

For nearly a decade, Peter B. Bach, MD, MAPP, Director of the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center in New York, has been a leading voice in sounding the alarm over the escalating cost of cancer drugs and in seeking a solution to the problem. In 2012, Dr....

colorectal cancer

Pilot Study Shows Promise of Neoadjuvant Chemotherapy Without Routine Radiotherapy in Patients With Locally Advanced Rectal Cancer

Neoadjuvant chemoradiotherapy delays administration of optimal chemotherapy in stage II to III rectal cancer. In a pilot study reported in the Journal of Clinical Oncology, Schrag et al assessed outcomes with neoadjuvant FOLFOX (fluorouracil, leucovorin, oxaliplatin)/bevacizumab (Avastin) with...

Advertisement



Advertisement


Advertisement